OralTherapeutic flag Cosmetic cross-reference

Quinine

CAS 130-95-0

Quinine (CAS 130-95-0) is a Phase 4 pharmaceutical compound with 7 bioactivity targets and 349 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

349

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Quinine

CAS Number

130-95-0

UNII

A7V27PHC7A

InChIKey

LOUPRKONTZGTKE-WZBLMQSHSA-N

ChEMBL ID

CHEMBL170

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

black box warningnatural productoraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL170 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 15 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	4831.390640668524 nM	358	-
-	IC50	2.3218789041095893 ug.mL-1	73	-
-	AC50	26043.852777777778 nM	36	-
-	EC50	35140.833333333336 nM	12	-
-	Ki	18472.30769230769 nM	11	-
-	Potency	22748.44 nM	5	-
-	MIC	395000 nM	1	-
-	MIC	100 ug.mL-1	1	-
Potassium voltage-gated channel subfamily H member 2 Ion channel	-	-	-	Homo sapiens
Multidrug resistance protein 1 Transporter	Ki	4.92	-	Homo sapiens
Hemoglobin subunit alpha Secreted	-	-	-	Homo sapiens
Potassium voltage-gated channel subfamily B member 2 Ion channel	IC50	4.9	-	Homo sapiens
Solute carrier family 22 member 1 Transporter	IC50	4.29	-	Homo sapiens
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel	IC50	5.36	-	Homo sapiens
Equilibrative nucleoside transporter 4 Transporter	Ki	4.57	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Drug abuse	686	1302.306	10013654
Toxicity to various agents	476	326.796	10070863
Thrombotic microangiopathy	87	161.133	10043645
Labile blood pressure	45	147.959	10023533
Somatic symptom disorder	40	114.875	10078076
Sacroiliitis	41	102.832	10039361
Cinchonism	15	102.464	10009189
Drug ineffective	145	94.041	10013709
Lipase increased	54	82.125	10024574
Poisoning	59	79.372	10061355
Off label use	112	76.508	10053762
Haematemesis	83	74.544	10018830
Hepatic ischaemia	22	73.687	10056328
Exposure via ingestion	29	65.378	10073302
Hepatorenal syndrome	29	64.954	10019846
Hyponatraemia	142	61.738	10021036
Fall	291	60.151	10016173
Product dose omission issue	7	60.025	10084406
Sedation complication	42	59.309	10079741
Acute kidney injury	285	58.524	10069339
Cognitive disorder	87	58.09	10057668
Muscle relaxant therapy	12	56.496	10058909
Blood calcium decreased	56	54.764	10005395
Contraindicated product administered	3	52.566	10078504
Agitated depression	14	50.813	10001496
Microangiopathic haemolytic anaemia	18	50.525	10027527
Blood sodium decreased	54	48.973	10005802
Retinal toxicity	17	45.754	10048955
Mood altered	41	45.084	10027940
Infusion related reaction	13	44.145	10051792
Creatinine renal clearance decreased	38	43.351	10011372
Rheumatoid arthritis	11	43.076	10039073
Nephrogenic systemic fibrosis	26	42.312	10067467
Electrocardiogram QT prolonged	83	42.137	10014387
Depressed level of consciousness	83	41.274	10012373
Rhabdomyolysis	86	41.129	10039020
Coronary artery disease	70	40.993	10011078
Drug intolerance	22	40.893	10061822
Synovitis	3	40.74	10042868
Treatment failure	8	40.348	10066901
Atrioventricular block	32	39.583	10003671
Intentional product misuse	82	38.905	10074903
Cardiac arrest	116	38.81	10007515
Fatigue	170	38.13	10016256
Glossodynia	3	37.512	10018388
Hepatic enzyme increased	8	37.434	10060795
Hypomagnesaemia	53	37.189	10021027
Lethargy	76	36.94	10024264
Hypovolaemia	33	35.911	10021137
Orthostatic hypotension	59	35.391	10031127

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
K 2P 18.1	Channel blocker	-	-
K v 2.2 KCNB2	Channel blocker	4.9 pIC50	9612272
Plasma membrane monoamine transporter SLC29A4	Inhibition	4.570000171661377 pKi	16099839\|27506881
Plasmodium falciparum purine nucleoside phosphorylase	Inhibitor	6.860000133514404 pKi	30602534
TAS2R14 TAS2R14	Agonist	-	20022913
TAS2R40 TAS2R40	Agonist	-	20022913
VRAC	Channel blocker	-	-

SOURCE PharmGKB 1 phenotype row

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

G6PD (PA28469) G6PD deficiency

G6PD deficiency is associated with Anemia, Hemolytic when treated with quinine.

Evidence: -; PMID 407765

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
QUININE	9071	SU	MTHSPL
Quinine	9071	SU	MTHSPL
quinine	9071	IN	RXNORM
quiNINE	9071	TMSY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Quinine used for in pharmaceutical contexts?

Quinine (CAS 130-95-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Quinine?

Quinine has 349 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug abuse, Toxicity to various agents, Thrombotic microangiopathy, Labile blood pressure, Somatic symptom disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Quinine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Quinine with EU status "restricted".

What clinical phase is Quinine in?

Quinine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Quinine?

Quinine has 15 bioactivity rows in this page query. Rendered target entries include Potassium voltage-gated channel subfamily H member 2, Multidrug resistance protein 1, Hemoglobin subunit alpha, Potassium voltage-gated channel subfamily B member 2, Solute carrier family 22 member 1.